Personalized medicine in oncology

被引：0

作者：

Loersch, Alisa Martina ^{[1
,2
,3
]}

Jung, Johannes ^{[1
,2
,3
,4
]}

Lange, Sebastian ^{[1
,3
,5
,6
]}

Pfarr, Nicole ^{[1
,3
,4
,7
]}

Mogler, Carolin ^{[1
,3
,4
,6
,7
]}

Illert, Anna Lena ^{[1
,2
,3
,4
,6
,8
]}

机构：

[1] Tech Univ Munich, Zent Personalisierte Med ZPM, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany

[2] Tech Univ Munich, Klin & Poliklin Hals Nasen & Ohrenheilkunde, Klinikum Rechts Isar, Munich, Germany

[3] Standort Tech Univ Munchen, Bayer Zent Krebsforschung BZKF, Munich, Germany

[4] Deutsch Konsortium Translationale Krebsforschung D, Munich, Germany

[5] Tech Univ Munich, Klin & Poliklin Innere Med 2, Klinikum Rechts Isar, Munich, Germany

[6] Tech Univ Munich, Klinikum Rechts Isar, Comprehens Canc Ctr Munchen, Munich, Germany

[7] Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Munich, Germany

[8] Univ Klinikum Freiburg, Klin Innere Med I, Abteilungfur Hamatol Onkol & Stammzelltransplantat, Freiburg, Germany

来源：

PATHOLOGIE | 2024年 / 45卷 / 03期

关键词：

Next-generation sequencing; Personalized medicine; Targeted therapy; Tumor-agnostic therapy; Biomarker; CANCER-PATIENTS; CHOLANGIOCARCINOMA; DECISIONS;

D O I：

10.1007/s00292-024-01315-8

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Due to the considerable technological progress in molecular and genetic diagnostics as well as increasing insights into the molecular pathogenesis of diseases, there has been a fundamental paradigm shift in the past two decades from a "one-size-fits-all approach" to personalized, molecularly informed treatment strategies. Personalized medicine or precision medicine focuses on the genetic, physiological, molecular, and biochemical differences between individuals and considers their effects on the development, prevention, and treatment of diseases. As a pioneer of personalized medicine, the field of oncology is particularly noteworthy, where personalized diagnostics and treatment have led to lasting change in the treatment of cancer patients in recent years. In this article, the significant change towards personalized treatment concepts, especially in the field of personalized oncology, will be discussed and examined in more detail.

引用

页码：180 / 189

页数：10

共 64 条

[1] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[2]

American Cancer Society Health & Medical Content Team, 2023, TUMOR AGNOSTIC DRUGS

[3]

Annalen B etal, 2022, LEITLINIE LUNGENKARZ

[4] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma [J].

Arai, Yasuhito ;

Totoki, Yasushi ;

Hosoda, Fumie ;

Shirota, Tomoki ;

Hama, Natsuko ;

Nakamura, Hiromi ;

Ojima, Hidenori ;

Furuta, Koh ;

Shimada, Kazuaki ;

Okusaka, Takuji ;

Kosuge, Tomoo ;

Shibata, Tatsuhiro .

HEPATOLOGY, 2014, 59 (04) :1427-1434

[5] Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) a randomised, open-label, multicentre, phase 3 trial [J].

Bidard, Francois-Clement ;

Hardy-Bessard, Anne-Claire ;

Dalenc, Florence ;

Bachelot, Thomas ;

Pierga, Jean-Yves ;

Rouge, Thibault de la Motte ;

Sabatier, Renaud ;

Dubot, Coraline ;

Frenel, Jean-Sebastien ;

Ferrero, Jean Marc ;

Ladoire, Sylvain ;

Levy, Christelle ;

Mouret-Reynier, Marie-Ange ;

Lortholary, Alain ;

Grenier, Julien ;

Chakiba, Camille ;

Stefani, Laetitia ;

Plaza, Jerome Edouard ;

Clatot, Florian ;

Teixeira, Luis ;

D'Hondt, Veronique ;

Vegas, Helene ;

Derbel, Olfa ;

Garnier-Tixidre, Claire ;

Canon, Jean-Luc ;

Pistilli, Barbara ;

Andre, Fabrice ;

Arnould, Laurent ;

Pradines, Anne ;

Bieche, Ivan ;

Callens, Celine ;

Lemonnier, Jerome ;

Berger, Frederique ;

Delaloge, Suzette .

LANCET ONCOLOGY, 2022, 23 (11) :1367-1377

[6]

Bitzer M, 2020, OPTIONS JCO PRECIS O, V4

[7] How to Integrate Personalized Medicine into Prevention? Recommendations from the Personalized Prevention of Chronic Diseases (PRECeDI) Consortium [J].

Boccia, Stefania ;

Pastorino, Roberta ;

Ricciardi, Walter ;

Adany, Roza ;

Barnhoorn, Floris ;

Boffetta, Paolo ;

Cornel, Martina C. ;

De Vito, Corrado ;

Gray, Muir ;

Jani, Anant ;

Lang, Michael ;

Roldan, Jim ;

Rosso, Annalisa ;

Sanchez, Jose Manuel ;

Van Dujin, Cornelia M. ;

Van El, Carla G. ;

Villari, Paolo ;

Zawati, Ma'n H. .

PUBLIC HEALTH GENOMICS, 2020, 22 (5-6) :208-214

[8] Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review [J].

Boscoe, Audra N. ;

Rolland, Catherine ;

Kelley, Robin Kate .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (04) :751-+

[9]

Büttner R, 2019, PATHOLOGE, V40, P276, DOI 10.1007/s00292-019-0605-4

[10] The role of B cells in COVID-19 infection and vaccination [J].

Chen, Shiru ;

Guan, Fei ;

Candotti, Fabio ;

Benlagha, Kamel ;

Camara, Niels Olsen Saraiva ;

Herrada, Andres A. ;

James, Louisa K. ;

Lei, Jiahui ;

Miller, Heather ;

Kubo, Masato ;

Ning, Qin ;

Liu, Chaohong .

FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 6 7 →